Prognostic utility of postoperative C-reactive protein for posthepatectomy liver failure

Archives of Surgery

Volumn 143, Issue 3, 2008, Pages 247-253

  Rahman, Sakhawat H ^a,b   Evans, Jessica ^a   Toogood, Giles J ^a   Lodge, Peter A ^a   Prasad, K Rajendra ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN;

ADULT; AGED; ARTICLE; ASCITES; BLOOD CLOTTING DISORDER; BRAIN DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DEATH; FEMALE; HUMAN; HYPERBILIRUBINEMIA; LIVER FAILURE; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; MULTIVARIATE ANALYSIS; POSTHEPATECTOMY LIVER FAILURE; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SEPSIS; STANDARD; STATISTICAL SIGNIFICANCE; SURGICAL MORTALITY; UNITED KINGDOM;

ADULT; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; HEPATECTOMY; HUMANS; LIVER FAILURE; MIDDLE AGED; POSTOPERATIVE PERIOD; PROGNOSIS;

EID: 41149140900     PISSN: 00040010     EISSN: 15383644     Source Type: Journal    
DOI: 10.1001/archsurg.2007.75     Document Type: Article

References (33)

1. Fong Y. Surgical therapy of hepatic colorectal metastasis. CA Cancer J Clin. 1999;49(4):231-255.
2. Rodgers MS, McCall JL. Surgery for colorectal liver metastases with hepatic lymph node involvement: a systematic review. Br J Surg. 2000;87(9):1142-1155.
3. Lodge JP, Menon KV, Fenwick SW, Prasad KP, Toogood G. In-contiguity and non-anatomical extension of right hepatic trisectionectomy for liver metastases. Br J Surg. 2005;92(3):340-347.
4. Minagawa M, Makuuchi M, Torzilli G, et al. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results. Ann Surg. 2000;231(4):487-499.
5. Scheele J, Strang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg. 1995;19(1):59-71.
6. Malafosse R, Penna C, Sa CA, Nordlinger B. Surgical management of hepatic metastases from colorectal malignancies. Ann Oncol. 2001;12(7):887-894.
7. Farges O, Malassagne B, Flejou JF, et al. Risk of major liver resection in patients with underlying chronic liver disease: a reappraisal. Ann Surg. 1999;229(2):210-215.
8. Shirabe K, Shimada M, Gion T, et al. Postoperative liver failure after major hepatic resection for hepatocellular carcinoma in the modern era with special reference to remnant liver volume. J Am Coll Surg. 1999;188(3):304-309.
9. Schindl MJ, Redhead DN, Fearon KC, Garden OJ, Wigmore SJ; Edinburgh Liver Surgery and Transplantation Experimental Research Group (eLISTER). The value of residual liver volume as a predictor of hepatic dysfunction and infection after major liver resection. Gut. 2005;54(2):289-296.
10. Nonami T, Nakao A, Kurokawa T, et al. Blood loss and ICG clearance as best prognostic markers of post-hepatectomy liver failure. Hepatogastroenterology. 1999;46(27):1669-1672.
11. Nanashima A, Yamaguchi H, Tanaka K, et al. Preoperative serum hyaluronic acid level as a good predictor of posthepatectomy complications. Surg Today. 2004;34(11):913-919.
12. Lan AK, Luk HN, Goto S, et al. Stress response to hepatectomy in patients with a healthy or diseased liver. World J Surg. 2003;27(7):761-764.
13. Kushner I, Rzewnicki DL. The acute phase response: general aspects. Baillieres Clin Rheumatol. 1994;8(3):513-530.
14. Mazlam MZ, Hodgson HJ. Interrelations between interleukin-6, interleukin-1 β, plasma C-reactive protein values, and in vitro C-reactive protein generation in patients with inflammatory bowel disease. Gut. 1994;35(1):77-83.
15. Castell JV, Gomez-Lechon MJ, David M, et al. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology. 1990;12(5):1179-1186.
16. Jialal I, Devaraj S, Venugopal SK. C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension. 2004;44(1):6-11.
17. Kuta AE, Baum LL. C-reactive protein is produced by a small number of normal human peripheral blood lymphocytes. J Exp Med. 1986;164(1):321-326.
18. Streetz KL, Luedde T, Manns MP, et al. Interleukin 6 and liver regeneration. Gut. 2000;47(2):309-312.
19. Koga M, Ogasawara H. Induction of hepatocyte mitosis in intact adult rat by interleukin-1 α and interleukin-6. Life Sci. 1991;49(17):1263-1270.
20. Maione D, Carlo E, Li W, et al. Coexpression of IL-6 and soluble IL-6R causes nodular regenerative hyperplasia and adenomas of the liver. EMBO J. 1998;17(19):5588-5597.
21. Cressman DE, Greenbaum LE, DeAngelis RA, et al. Liver failure and defective hepatocyte regeneration in interleukin-6 - deficient mice. Science. 1996;274(5291):1379-1383.
22. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation. 2002;106(12):1439-1441.
23. Ballou SP, Lozanski G. Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine. 1992;4(5):361-368.
24. Tilg H, Vannier E, Vachino G, Dinarello C, Mier JW. Anti-inflammatory properties of hepatic acute phase proteins: preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1 β synthesis by human peripheral blood mononuclear cells. J Exp Med. 1993;178(5):1629-1636.
25. Wüstefeld T, Rakemann T, Kubicka S, Manns MP, Trautwein C. Hyperstimulation with interleukin 6 inhibits cell cycle progression after hepatectomy in mice. Hepatology. 2000;32(3):514-522.
26. Jin X, Zimmers TA, Perez EA, Pierce RH, Zhang Z, Koniaris LG. Paradoxical effects of short- and long-term interleukin-6 exposure on liver injury and repair. Hepatology. 2006;43(3):474-484.
27. Novelli G, Rossi M, Pretagostini R, et al. A 3-year experience with molecular adsorbent recirculating system (MARS): our results on 63 patients with hepatic failure and color Doppler ultrasound evaluation of cerebral perfusion. Liver Int. 2003;23(suppl 3):10-15.
28. Felldin M, Friman S, Backman L, et al. Treatment with the molecular adsorbent recirculating system in patients with acute liver failure. Transplant Proc. 2003;35(2):822-823.
29. Lamesch P, Jost U, Schreuter D, et al. Molecular adsorbent recirculating system in patients with liver failure. Transplant Proc. 2001;33(7-8):3480-3482.
30. Kellersmann R, Gassell HJ, Buhler C, et al. Application of molecular adsorbent recirculating system in patients with severe liver failure after hepatic resection or transplantation: initial single-centre experiences. Liver. 2002;22(suppl 2):56-58.
31. Mullhaupt B, Kullak-Ublick GA, Ambuhl P, et al. First clinical experience with molecular adsorbent recirculating system (MARS) in six patients with severe acute or chronic liver failure. Liver. 2002;22(suppl 2):59-62.
32. van de Kerkhove M-P, de Jong KP, Rijken AM, et al. MARS treatment in post-hepatectomy liver failure. Liver Int. 2003;23(suppl 3):44-51.
33. Szalai AJ, McGrory MA. Varied biological functions of C-reactive protein: lessons learned from transgenic mice Immunol Res. 2002;26(1-3):279-287.